Open AccessSuccessful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
Author(s) -
Makimoto Go,
Shimonishi Atsushi,
Ohashi Kadoaki,
Ninomiya Kiichiro,
Higo Hisao,
Kato Yuka,
Fujii Masanori,
Kubo Toshio,
Ichihara Eiki,
Hotta Katsuyuki,
Tabata Masahiro,
Maeda Yoshinobu,
Kiura Katsuyuki
Publication year - 2022
Publication title -
case reports in oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.365
H-Index - 19
ISSN - 1662-6575
DOI - 10.1159/000524326
Subject(s) - case report
Tepotinib, the novel MET-tyrosine kinase inhibitor, shows an antitumor effect for patients with non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. In January 2022, the AmoyDx® Pan Lung Cancer polymerase chain reaction Panel (AmoyDx® panel), which had a shorter turnaround time than the conventional test, was launched in Japan as a tepotinib companion test. We report a patient with an advanced MET-mutant NSCLC promptly diagnosed using the AmoyDx® panel and successfully treated with tepotinib. Although the patient’s performance status (PS) worsened due to the rapid tumor progression and lung abscess formation, the tumor shrank immediately after tepotinib treatment with marked PS improvement.